292 related articles for article (PubMed ID: 2706620)
1. Sensitivity of human melanoma cells to L-dopa and DL-buthionine (S,R)-sulfoximine.
Kable EP; Favier D; Parsons PG
Cancer Res; 1989 May; 49(9):2327-31. PubMed ID: 2706620
[TBL] [Abstract][Full Text] [Related]
2. Glutathione depletion by L-buthionine sulfoximine antagonizes taxol cytotoxicity.
Liebmann JE; Hahn SM; Cook JA; Lipschultz C; Mitchell JB; Kaufman DC
Cancer Res; 1993 May; 53(9):2066-70. PubMed ID: 8097674
[TBL] [Abstract][Full Text] [Related]
3. Mitomycin C sensitivity in human bladder cancer cells: possible role of glutathione and glutathione transferase in resistance.
Xu BH; Gupta V; Singh SV
Arch Biochem Biophys; 1994 Jan; 308(1):164-70. PubMed ID: 8311448
[TBL] [Abstract][Full Text] [Related]
4. Buthionine sulfoximine induction of gamma-L-glutamyl-L-cysteine synthetase gene expression, kinetics of glutathione depletion and resynthesis, and modulation of carmustine-induced DNA-DNA cross-linking and cytotoxicity in human glioma cells.
Ali-Osman F; Antoun G; Wang H; Rajagopal S; Gagucas E
Mol Pharmacol; 1996 Jun; 49(6):1012-20. PubMed ID: 8649339
[TBL] [Abstract][Full Text] [Related]
5. Glutathione depletion by DL-buthionine-SR-sulfoximine (BSO) potentiates X-ray-induced chromosome lesions after liquid holding recovery.
Bertsche U; Schorn H
Radiat Res; 1986 Mar; 105(3):351-69. PubMed ID: 3754339
[TBL] [Abstract][Full Text] [Related]
6. Buthionine sulfoximine enhances glutathione-but attenuates glutamate-stimulated cell proliferation.
Kang YJ
Cell Mol Biol Res; 1995; 41(2):131-6. PubMed ID: 8581064
[TBL] [Abstract][Full Text] [Related]
7. Relationship of cellular glutathione to the cytotoxicity and resistance of seven platinum compounds.
Meijer C; Mulder NH; Timmer-Bosscha H; Sluiter WJ; Meersma GJ; de Vries EG
Cancer Res; 1992 Dec; 52(24):6885-9. PubMed ID: 1458477
[TBL] [Abstract][Full Text] [Related]
8. Chemosensitization of L-phenylalanine mustard by the thiol-modulating agent buthionine sulfoximine.
Kramer RA; Greene K; Ahmad S; Vistica DT
Cancer Res; 1987 Mar; 47(6):1593-7. PubMed ID: 3815359
[TBL] [Abstract][Full Text] [Related]
9. Alterations in glutathione and glutathione-related enzymes in a multidrug-resistant small cell lung cancer cell line.
Cole SP; Downes HF; Mirski SE; Clements DJ
Mol Pharmacol; 1990 Feb; 37(2):192-7. PubMed ID: 1968221
[TBL] [Abstract][Full Text] [Related]
10. Long-term buthionine-sulfoximine-mediated toxicity in cultured hepatoma cell lines.
Dierickx PJ
Res Commun Chem Pathol Pharmacol; 1990 Mar; 67(3):423-6. PubMed ID: 2160706
[TBL] [Abstract][Full Text] [Related]
11. Effect of D,L-buthionine-S,R-sulfoximine on cytotoxicity and DNA cross-linking induced by bifunctional DNA-reactive cytostatic drugs in human melanoma cells.
Hansson J; Edgren M; Ehrsson H; Ringborg U; Nilsson B
Cancer Res; 1988 Jan; 48(1):19-26. PubMed ID: 3334994
[TBL] [Abstract][Full Text] [Related]
12. Cyclophosphamide resistance in medulloblastoma.
Friedman HS; Colvin OM; Kaufmann SH; Ludeman SM; Bullock N; Bigner DD; Griffith OW
Cancer Res; 1992 Oct; 52(19):5373-8. PubMed ID: 1356617
[TBL] [Abstract][Full Text] [Related]
13. Glutathione and related enzymes in rat brain tumor cell resistance to 1,3-bis(2-chloroethyl)-1-nitrosourea and nitrogen mustard.
Evans CG; Bodell WJ; Tokuda K; Doane-Setzer P; Smith MT
Cancer Res; 1987 May; 47(10):2525-30. PubMed ID: 2882834
[TBL] [Abstract][Full Text] [Related]
14. Synergistic cytotoxicity of buthionine sulfoximine (BSO) and intensive melphalan (L-PAM) for neuroblastoma cell lines established at relapse after myeloablative therapy.
Anderson CP; Reynolds CP
Bone Marrow Transplant; 2002 Aug; 30(3):135-40. PubMed ID: 12189530
[TBL] [Abstract][Full Text] [Related]
15. Effect of buthionine sulfoximine and ethacrynic acid on cytotoxic activity of mitomycin C analogues BMY 25282 and BMY 25067.
Xu BH; Singh SV
Cancer Res; 1992 Dec; 52(23):6666-70. PubMed ID: 1423311
[TBL] [Abstract][Full Text] [Related]
16. Modulation of glutathione level in cultured human melanoma cells.
Karg E; Brötell H; Rosengren E; Rorsman H
Acta Derm Venereol; 1989; 69(2):137-41. PubMed ID: 2564231
[TBL] [Abstract][Full Text] [Related]
17. Effect of glutathione depletion by L-buthionine sulfoximine on the cytotoxicity of cyclophosphamide in single and fractionated doses to EMT6/SF mouse tumors and bone marrow.
Ono K; Shrieve DC
J Natl Cancer Inst; 1987 Oct; 79(4):811-5. PubMed ID: 3477662
[TBL] [Abstract][Full Text] [Related]
18. Potentiation of melphalan cytotoxicity in human ovarian cancer cell lines by glutathione depletion.
Green JA; Vistica DT; Young RC; Hamilton TC; Rogan AM; Ozols RF
Cancer Res; 1984 Nov; 44(11):5427-31. PubMed ID: 6488194
[TBL] [Abstract][Full Text] [Related]
19. The role of glutathione in lymphocyte activation. I. Comparison of inhibitory effects of buthionine sulfoximine and 2-cyclohexene-1-one by nuclear size transformation.
Hamilos DL; Wedner HJ
J Immunol; 1985 Oct; 135(4):2740-7. PubMed ID: 4031498
[TBL] [Abstract][Full Text] [Related]
20. Glutathione as a determinant of cellular response to doxorubicin.
Lee FY; Vessey AR; Siemann DW
NCI Monogr; 1988; (6):211-5. PubMed ID: 3352767
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]